Resumos
Índice de Palavras-chave
|
Voltar |
β-LACTAMASE [
16-1]
16S. [
115-1]
AEDES AEGYPTI [
8-2]
ALVEOLI NECROSIS [
41-1]
ANTIBACTERIAL ACTIVITY [
57-1]
ANTIBACTERIAL AGENTS [
28-1]
ANTIBACTERIAL SUSCEPTIBILITY [
61-1]
ANTIMICROBIAL ACTIVITY [
62-1]
ANTIMICROBIAL RESISTANCE [
59-1]
ANTIMICROBIAL SUSCEPTIBILITY [
21-1]
AUTOMATED METHOD [
132-1]
BACTEREMIA [
132-1]
BACTERIA [
96-1], [
99-2]
BACTERIAL INFECTIONS [
115-1]
BACTERIAL MENINGITIS [
75-1]
BACTERIAL RESISTANCE [
26-2], [
33-1]
BETA-HEMOLISE [
41-1]
BETA-LACTAMASES [
26-1]
BIOFILM [
21-1], [
28-1], [
64-2], [
96-1]
BIOFILMS [
34-1], [
102-1]
BLANDM-1 [
129-1]
BLOOD CULTURE [
130-1]
BLOODSTREAM [
61-1], [
130-2]
BLOODSTREAM INFECTION [
130-1]
BOVINE [
127-3]
BUNDLE [
22-1]
CANDIDA ALBICANS [
64-2], [
102-1]
CARBAPENEMASE [
14-1], [
31-2]
CARBAPENEMASE; ; KLE [
14-2]
CARBAPENEMASES [
23-2]
CATIONIC ANTIMICROBIAL PEPTIDES [
34-1]
CELL CULTURE [
34-1], [
36-1]
CHIKUNGUNYA [
8-3]
CHLAMYDIA PNEUMONIAE [
37-2]
CHLAMYDIA TRACHOMATIS [
37-1]
CLADINA DENDROIDES [
128-1]
CLINICAL [
8-3]
COLISTIN [
23-2]
COLONIZATION [
39-1]
COMPLEX WOUNDS. [
46-1]
CONFOCAL MICROSCOPY [
34-1]
CONVENTIONAL PCR [
39-1]
COST [
22-1]
CROSS-CONTAMINATION [
32-1]
CRYPTOCOCCAL MENINGITIS [
52-1]
CURCUMIN [
102-1]
DECONTAMINATION TECHNIQUES [
32-1]
DENGUE [
8-3]
DENGUE VIRUS [
8-2]
DENTAL BIOFILM [
123-1]
DENTAL CARIES [
36-1], [
123-1]
DESCRITIVE EPIDEMIOLOGY [
56-1]
DIABETIC FOOT WOUND [
62-1]
DIAGNOSTIC [
8-3], [
37-1], [
37-2]
DIFFUSION AGAR [
128-2]
DISK DIFFUSION TEST [
128-1]
DOG [
63-1]
DRUG-RESISTANT [
29-1]
E-TEST [
132-1]
E. FAECALIS [
23-1]
EFFLUX PUMP [
16-1]
ENTEROAGGREGATIVE ESCHERICHIA COLI [
21-1]
ENTEROBACTER SPP. [
31-2]
ENTEROBACTERIACEAE [
30-1], [
129-1]
ENTEROBACTERIAS [
26-1], [
26-2]
ENVIRONMENT [
30-1]
EPIDEMIOLOGICAL [
127-3]
EPIDEMIOLOGY [
8-2], [
65-2]
ESBL [
30-1], [
31-2], [
42-1]
ESCHERICHIA COLI [
99-1]
EXTRACELLULAR MATRIX [
123-1]
FECAL MICROBIOTA [
35-1]
FEMA [
39-1]
HEALING [
99-2]
HEALTHCARE CENTER PATIENT. [
46-1]
HIGH-RESOLUTION MELTING [
33-1]
HIV [
52-1], [
65-2]
ICU [
30-1]
IMLSB [
11-1]
INFECTION [
33-1], [
42-1]
INTENSIVE CARE UNIT [
11-1], [
22-1]
KERATINOCYTES [
64-2]
KLEBSIELLA PNEUMONIAE [
14-1], [
130-2]
KLEBSIELLA PNEUMONIAE; [
14-2]
KPC [
14-1], [
14-2], [
130-2]
LACTOBACILLUS SP [
35-1]
LEMON GRASS [
99-1]
LICHEN EXTRACTS [
128-1]
LUKS-F [
39-1]
MALDI-TOF [
59-1]
MANHEIMIOSIS [
41-1]
MBIC [
21-1]
MECA [
39-1]
MECHANICAL VENTILATION; [
42-1]
METHICILLIN [
33-1]
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUR [
102-1]
MIC [
57-1]
MICROBIAL SENSITIVITY TESTS [
34-1], [
36-1]
MICROBIOLOGICAL [
127-3]
MICROBIOLOGICAL CONTAMINATION [
32-1]
MINIMAL INHIBITORY CONCENTRATION [
10-1]
MOLECULAR DIAGNOSIS [
75-1]
MORTALITY [
22-1]
MRSA [
11-1]
MULTIDRUG RESISTANCE [
63-1]
MULTIDRUG-RESISTANT BACTERIA [
10-1], [
10-2]
MULTIRESISTANT [
23-2], [
65-1]
MUSA [
99-2]
MYCOBACTERIUM PHLEI [
128-2]
MYCOBACTERIUM TUBERCULOSIS [
17-2], [
17-3], [
29-1]
NANOPARTICLES [
57-1]
NITRATE REDUCTION METHOD [
29-1]
NOSOCOMIAL INFECTION [
14-1], [
14-2]
NOSOCOMIAL OUTBREAK [
14-1], [
14-2]
OBLIGATE ANAEROBES [
59-1]
ORIGANUM VULGARE [
10-1], [
10-2]
PEG-LID [
21-1]
PENITENTIARY SYSTEM [
17-2]
PEPTIDES [
36-1]
PFGE [
23-2]
PHAGE DISPLAY [
37-1], [
37-2]
PHOTODYNAMIC THERAPY [
96-1]
PHYTOTHERAPY [
99-2]
PLANTS EXTRACTS [
128-2]
PLASMID [
129-1]
PLASMIDS [
75-1]
PMQR [
31-2]
PREVALENCE [
17-2]
PSEUDOMONAS [
16-1]
RAPID DIAGNOSIS [
130-1]
REAL TIME PCR [
75-1]
REAL TIME POLYMERASE CHAIN REACTION [
115-1]
REAL-TIME PCR [
17-2], [
17-3]
RELAPSED AND REFRACTORY [
52-1]
RESISTANCE [
16-1], [
30-1], [
65-1]
RESISTANCE; [
42-1]
RNA [
115-1]
ROBIN SEQUENCE [
35-1]
RUMINANT [
41-1]
S. AUREUS [
23-1]
SALMONELLA [
127-3]
SALMONELLA TYPHI [
61-1]
SANTO ANDRE [
56-1]
SEPSIS [
115-1]
SEROVARES [
127-3]
SOLIDAGO MICROGLOSSA [
62-1]
SPONGE [
32-1]
STAPHYLOCOCCUS AUREUS [
11-1], [
33-1], [
64-2], [
99-1]
STAPHYLOCOCCUS PSEUDINTERMEDIUS [
63-1]
STAPHYLOCOCCUS SAPROPHYTICUS [
28-1]
STAPHYLOCOCCUS SPP., [
132-1]
STREPTOCOCCUS MUTANS [
123-1]
SUSCEPTIBILITY PROFILE [
26-1]
SUSCEPTIBILITY PROFILE. [
46-1]
SUSCEPTIBILITY TO ANTIFUNGAL AGENTS [
52-1]
SYNERGISM [
10-2]
TEDIZOLID [
23-1]
TIGECYCLINE [
23-2]
TN3000 [
129-1]
TOXICITY [
64-2]
TUBERCULOSIS [
17-2], [
17-3], [
29-1], [
56-1], [
65-1], [
65-2]
URINARY TRACT INFECTION [
26-2], [
28-1]
UTI [
26-1]
VANCOMYCIN [
132-1]
VENTILATOR-ASSOCIATED PNEUMONIA [
22-1]
WOUND [
99-2]
YEAST [
96-1]